Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response characterization in participants from a posdinemab study
NL-OMON60256Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of posidinemab in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Feb 2025; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60256.